Skip to main content
Premium Trial:

Request an Annual Quote

En Route to the $1000 Genome

Tech Review has an article on Oxford Nanopore Technologies, one of the newest next-gen sequencing companies to enter the race for the $1000 genome. Because nanopore sequencing can analyze individual strands of DNA, the process saves time and money on sample prep. "We think we're the only label-free technology out there," Gordon Sanghera says. "There's no labeling. There's no amplification. And that really does take out the bulk of what you're doing." The company has raised about $20 million in funding and hopes to keep pace with Pacific Biosciences and have a machine for sale in about two years.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.